Teleflex (NYSE:TFX) Receives Hold Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Teleflex (NYSE:TFX) in a report released on Wednesday morning,Benzinga reports.

Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada lowered shares of Teleflex from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $220.00 to $155.00 in a research note on Friday, February 28th. Citizens Jmp lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Raymond James lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Morgan Stanley cut their target price on shares of Teleflex from $275.00 to $191.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Finally, StockNews.com lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $182.63.

Teleflex Price Performance

Shares of NYSE:TFX opened at $135.46 on Wednesday. The stock has a market cap of $6.28 billion, a PE ratio of 26.93, a PEG ratio of 1.73 and a beta of 1.21. The company’s fifty day moving average is $168.73 and its 200 day moving average is $199.15. Teleflex has a 52 week low of $128.55 and a 52 week high of $249.90. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The firm had revenue of $795.40 million for the quarter, compared to analysts’ expectations of $813.24 million. Research analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, March 7th will be paid a dividend of $0.34 per share. The ex-dividend date is Friday, March 7th. This represents a $1.36 annualized dividend and a yield of 1.00%. Teleflex’s payout ratio is 95.77%.

Hedge Funds Weigh In On Teleflex

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Siemens Fonds Invest GmbH purchased a new position in shares of Teleflex in the 4th quarter worth $1,336,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Teleflex in the 4th quarter worth $6,528,000. Jefferies Financial Group Inc. boosted its stake in shares of Teleflex by 9.3% during the 4th quarter. Jefferies Financial Group Inc. now owns 4,837 shares of the medical technology company’s stock worth $861,000 after purchasing an additional 412 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Teleflex by 59.2% during the 4th quarter. Mackenzie Financial Corp now owns 36,281 shares of the medical technology company’s stock worth $6,457,000 after purchasing an additional 13,488 shares during the period. Finally, Forum Financial Management LP boosted its stake in shares of Teleflex by 48.6% during the 4th quarter. Forum Financial Management LP now owns 1,293 shares of the medical technology company’s stock worth $230,000 after purchasing an additional 423 shares during the period. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.